Abstract. Pancreatic cancer cells (PCCs) are surrounded by an abundant stroma, which is produced by pancreatic stellate cells (PSCs). PSCs promote tumor cell proliferation and invasion. The objective of the current study was to identify compounds that suppress PSC activation. Gene expression profiles of cancer‑derived fibroblasts and normal fibroblasts were used, and the pathway analysis suggested altered pathways that were chosen for validation. It was found that the ‘neuroactive ligand-receptor interaction’ pathway from the Kyoto Encyclopedia of Genes and Genomes pathway analysis was one of the altered pathways. Several compounds related with this pathway were chosen, and changes in PSC activity were investigated using fluorescence staining of lipid droplets, reverse transcription-quantitative PCR, western blotting, and invasion and migration assays. Among these candidates, duloxetine, a serotonin-noradrenaline reuptake inhibitor, was found to suppress PSC activation and disrupt tumor-stromal interaction. Thus, duloxetine may be a potential drug for suppressing PSC activation and pancreatic cancer growth.

Introduction
Pancreatic cancer is one of the most lethal cancers, with a 5-year survival rate of <9%. While its incidence is increasing, its mortality rate has remained unchanged (1). Patient response to existing therapy is limited (2). Therefore, to overcome these issues, there is an increasing and urgent need to discover new treatment options.

In clinical practice, the traditional drug discovery process is expensive and takes over a decade (3). Thus, repositioning clinically evaluated drugs can be a strategy for the rapid detection and application of new alternative therapeutic approaches (4).

Pancreatic stellate cells (PSCs) are myofibroblast-like cells and are located in the pancreatic stroma (5). PSCs have the ability to produce components of the extracellular matrix (ECM) and make the stroma stiff. During pancreatic damage due to inflammation and metabolic stress, PSCs are activated by growth factors/cytokines released from neighboring cells (6). Activated PSCs support the proliferation of cancer cells, as shown by some studies assessing the relationship between cancer cells and PSCs (7). Therefore, inactivating PSCs could potentially be a novel approach for pancreatic cancer treatment.

The aim of this study was to determine a promising compound for inactivating PSCs. To achieve this, gene expression profiles of cancer-associated fibroblasts (CAF) and normal fibroblasts were analyzed, and neuroactive ligand-receptor interaction pathway related to the cancer-associated PSCs was identified. We focused on duloxetine, a serotonin-noradrenaline reuptake inhibitor, as a potential compound for suppressing the activity of PSCs.
Identification of differentially expressed genes from public microarray data. Public gene expression profiles for GSE53524 were obtained from Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo). Data was analyzed, and a set of genes differentially expressed in CAFs and normal fibroblasts were identified. P-values <0.05 for microarray data were selected. Pathway enrichment analysis of targets was performed using the DAVID v6.8 (https://david.ncifcrf.gov/). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed for identified up- and down-regulated genes. P<0.05 was considered to indicate statistical significance.

Drugs. Duloxetine hydrochloride (cat. no. 040-34071, Wako Pure Chemicals) was dissolved in dimethyl sulfoxide (DMSO) at a final concentration of 10 mM and stored at -20°C. Paroxetine hydrochloride (cat. no. 168-24431, Wako Pure Chemicals), desloratadine (cat. no. D3787, TCI Chemicals), promethazine, amitriptyline hydrochloride (cat. no. A9165, Sigma-Aldrich Co.), Wnt-3a (cat. no. 5036-WN-010; R&D Systems), R-Spondin 1 (cat. no. 120-38; Peprotech), Noggin (cat. no. 120-10C; Invitrogen), R-Spondin 1 (cat. no. 120-38; Peprotech), Nicotinamide (cat. no. N0636; Sigma-Aldrich Co.), Y-27263 (cat. no. Y0503; Sigma-Aldrich Co.), and A83-01 (cat. no. 2939/10; R&D Systems). Organoid area measurements were performed using KEYENCE BZ-X analyzer.

Cell viability assay. Cell Titer-Glo Luminescent Cell Viability Assay (Promega Corp.) was used for assaying. PSCs (1x10^4 cells/well) were seeded in 96-well polystyrene cell culture microplates (cat. no. 655083, Greiner Bio-One International) and incubated at 37°C in a humidified atmosphere with 10% CO₂. After 24 h, the medium was aspirated and fresh DMEM containing 10% FBS and the candidate drugs at each concentration were added. Fluorescence was measured after 48 h. The emission value was measured as a control using a microplate reader (Infinite F200; Tecan), according to the manufacturer's instructions. Cell viability was evaluated as the ratio to the control.

Reverse transcription-quantitative polymerase chain reaction. For duloxetine treatment, we used the concentration of 10 µM. Total RNA was extracted from PSCs using a High Pure RNA Isolation Kit (cat. no. 11828665001, Roche), according to the manufacturer's instructions. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed using SYBR Green RT-PCR kit (cat. no. 170-8892; Bio-Rad Laboratories) and the CFX96 Real-Time PCR System (Bio-Rad Laboratories). Primers were purchased from Takara (Shiga, Japan). The primer sequences are listed in Table SI. The reactions were incubated at 50°C for 10 min, 95°C for 1 min, 95°C for 10 sec, 60°C for 30 sec for 39 cycles, 60°C for 5 sec, and 95°C for 5 sec. The quantity of messenger RNA (mRNA) was calculated using the 2^ΔΔCq method (13). mRNA expression was normalized using glyceraldehyde-3-phosphate dehydrogenase.

Western blotting. Cells were incubated for 48 h with each concentration of duloxetine (0, 1, 5 and 10 µM). Proteins were extracted using PRO-PREP Protein Extraction Solution (cat. no. 17081, iNtRON Biotechnology), according to the manufacturer's instructions. The protein concentration was measured using a NanoDrop 1000 Spectrophotometer.
(version 3.8.1; Thermo Fisher Scientific). After 48 h of incubation, cells were washed, and the medium was changed to DMEM with 0% FBS and was cultured overnight. Culture supernatants were collected in a centrifuge tube (cat. no. UFC900324, AmiconUltra; Merck Millipore) and centrifuged at 7,500 rpm for 30 min. Halt protease and phosphatase inhibitors (cat. no. 78442; Thermo Fisher Scientific) were added at a 1:1,000 dilution into the concentrated supernatants. Collected proteins (20 µg per lane from whole cell lysate) were fractionated on 4-15% Mini-PROTEAN TGX Precast Gels (cat. no. 456-1084; Bio-Rad Laboratories) and transferred to Trans-Blot Turbo Mini PVDF Transfer Packs (cat. no. 170-4156, Bio-Rad Laboratories) using a Trans-Blot Turbo Transfer Starter System (Bio-Rad Laboratories). The membrane was incubated at 4°C overnight with anti-Akt (Rabbit mAb, 1:1,000, cat. no. 4691; Cell Signaling Technology), anti-pAkt (Rabbit mAb, 1:1,000, cat. no. 4060; Cell Signaling Technology), anti-αSMA (Mouse mAb, 1:2,000, cat. no. M0851; Dako), anti-α-tubulin (Rabbit pAb, 1:2,000, cat. no. bs-50500R; Bioss), anti-Erk (Rabbit mAb, 1:1,000, cat. no. 4695; Cell Signaling Technology), anti-pErk (Rabbit pAb,1:1,000,cat.no.4370S;CellSignalingTechnology),anti-fibronectin(RabbitpAb,1:1,000,cat.no.ab2413;Abcam),anti-COL1A1(RabbitpAb,1:1,000,cat.no.84336S;Cell Signaling Technology),anti-IL-6(Mouse mAb,1:1,000,ab9324;Abcam),anti-periostin (POSTN; Rabbit pAb, 1:1,000, cat. no. ab14041; Abcam), anti-PP2A (Rabbit mAb, 1:1,000, cat. no. ab9324; Abcam), anti-β-actin (Mouse mAb, 1:1,000, cat. no. bs-8500R; Bioss), and anti-α-actin (Mouse mAb, 1:1,000, cat. no. ab14041; Abcam) antibodies. Membranes were then probed with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology). Immunoblots were detected by enhanced chemiluminescence using the ChemiDoc XRS System (Bio-Rad Laboratories) and were analyzed using Quantity One Software (Bio-Rad Laboratories). Each experiment was repeated three times.

**Statistical analysis.** All values are expressed as mean ± standard deviation (SD). For comparison between two groups only, data was analyzed with an unpaired two-tailed t-test. For comparison of multiple groups, comparisons were conducted using ANOVA, followed by Tukey-Kramer method. A P-value <0.05 was considered to indicate a statistically significant difference. Experiments were repeated at least three times. All statistical analyses were performed using GraphPad Prism 8.

**Results**

**Gene expression profiles of cancer-associated PSCs.** To identify the potential therapeutic targets of cancer-associated PSCs, we examined the gene expression profiles from public microarray data obtained from murine pancreatic CAFs and normal fibroblasts (GSE53524) (14). To identify the genes associated with CAFs in comparison to normal fibroblasts, probe sets with a P-value <0.05 for microarray data were selected. We found that many up-regulated genes were associated with several pathways of the KEGG pathway enrichment analysis (Fig. 1A). The hippo-signaling pathway and calcium-signaling pathway are reported potential target pathways in PSC activation (15,16). On the other hand, neuroactive ligand-receptor signaling in PSCs has not been studied. Therefore, we focused on this pathway.

To select candidate compounds, we referred to previous studies and focused on the gene targets in this pathway and selected compounds related to the pathway (17). In addition, we previously demonstrated high-throughput drug screening for detecting compounds that suppress the activity of PSCs (12). The result from this screening showed that these six compounds were included as candidate drugs for inactivating PSC function. Therefore, we selected these six compounds and confirmed their role in PSC inactivation. The following drugs were selected and evaluated: duloxetine, a 5-hydroxytryptamine and noradrenaline reuptake inhibitor; paroxetine, a selective serotonin (5-HT) reuptake inhibitor; desloratadine and promethazine, first-generation antihistamines; amitriptyline, a tricyclic antidepressant; and chlorpromazine, a dopamine receptor antagonist. These compounds are G-protein coupled receptor (GPCR) inhibitors, and they showed an affinity to GPCR (Table SII). Next, to assess the effect of these candidates on the PSC state, lipid droplet accumulation assaying for detecting quiescent PSCs was performed, as previously reported (11). Lipid accumulation in the cytoplasm was observed following treatment with five out of six compounds, and duloxetine showed the highest accumulation of lipid droplets (Fig. 1B). Therefore, duloxetine (Fig. 1C) was selected as a potential compound for suppressing the activity of PSCs.

**Duloxetine suppressed the activity of PSCs.** These results led us to further investigate the effects of duloxetine on PSC activation. First, we investigated the half-maximal inhibitory concentration of duloxetine for patient-derived PSCs and HPaSteC cells (hPSC). These concentrations ranged from 19.2 to 25.2 µM (Fig. 2A). Next, we investigated whether duloxetine suppresses the PSC activity, according to the previous report (6,11). The quiescent state is a reversible state (18). Therefore, we used live cells and demonstrated the changes of lipid droplets in the cytoplasm between duloxetine
treatments. To determine the changes in lipid droplets in live PSCs, Lipidye® staining was used for immunofluorescent staining (19). Lipid accumulation was observed with duloxetine treatment. Further, after washout and replacement of the drug-free medium, the intracellular lipid droplets disappeared (Fig. 2B). Next, we determined the expression of the PSC activation markers, alpha-smooth muscle actin (αSMA), and ECM proteins (collagen I, fibronectin and POSTN) by RT-qPCR and western blotting of whole-cell lysates. Duloxetine reduced the protein and mRNA expression of these markers in PSCs (Fig. 2C and D), suggesting that duloxetine suppressed the activity of PSCs. This effect was reversible, suggesting that duloxetine induced PSC quiescence.

**Duloxetine suppressed the proliferation of patient-derived organoids.** Next, to determine the effects of duloxetine on cancer cell growth, we used a PCC 2D culture and proliferation of human PCC cell line was directly attenuated by duloxetine treatment (Fig. 3A). It has been widely suggested that organoid models can epitomize in vivo-like growth and...
Figure 2. Duloxetine induces PSCs into a quiescent state. (A) Cell viability of PSCs in vitro. Each IC_{50} value is presented in the graph. (B) Representative photomicrographs of LipiDye staining of PSCs taken 0, 24 and 48 h after duloxetine treatment. DAPI was used for nuclear staining. After 48 h, the medium was washed off, fresh Dulbecco's modified Eagle's medium with 10% FBS was added, and the culture was continued. Magnifications, x200 (upper panels) and x400 (lower panels). Scale bar, 100 µm. (C) mRNA expression levels of αSMA and ECM proteins in PSCs. mRNA expression levels were normalized to GAPDH expression and are presented as the fold-change in gene expression relative to control PSCs. (D) Western blotting of αSMA and ECM proteins from whole cell lysate of PSCs. Values indicate densitometric ratios normalized to α-tubulin. **P<0.01, ***P<0.001, ****P<0.0001 vs. control group. PSCs, pancreatic stellate cells; αSMA, α-smooth muscle actin; ACTA2, actin α2 smooth muscle; ECM, extracellular matrix; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; hPSC, human pancreatic stellate cells; COL1A1, α-1 type-1 collagen; POSTN, periostin.
differentiation of tissues as compared to 2D cultures (20).

We found that duloxetine suppressed organoid formation and growth in organoids developed from the human surgical specimen (Fig. 3B), suggesting that duloxetine inhibits the growth of tumor organoids.

**Duloxetine suppressed tumor-stromal interaction.** Previous data showed that activated PSCs affect pancreatic cancer cell invasion and migration (21). To confirm whether duloxetine suppresses tumor-stromal interaction between pancreatic cancer cells (PCCs) and PSCs, an invasion and migration assay was performed. Compared to the control group, duloxetine itself did not attenuate PCC invasion and migration (Fig. 4A). Consistent with previous reports, co-culture with PSC supernatant stimulated PCC invasion and migration. However, this enhancement effect was abolished by co-culturing with a duloxetine-treated PSC supernatant (Fig. 4A and B), supporting the hypothesis that duloxetine suppresses the activity of PSCs and production of growth factors and cytokines that promote tumor-stromal interaction.

To further confirm the mechanism of duloxetine action, we used western blotting to determine the major secreted proteins and cytokines that attenuate tumor-stromal interaction from the PSC supernatant and whole cell lysates. Growth factors and pro-inflammatory cytokines released from adjacent cells cause PSC activation (22). Activated PSCs maintain their activated state by autocrine stimulation of cytokines, leading to proliferation, migration, and overproduction of the ECM (23). The duloxetine-treated PSC supernatant had fewer ECM protein amounts than those in the control (Fig. 4C). mRNA expression of connective tissue growth factor (CTGF), hepatocyte growth factor (HGF), interleukin-1β (IL-1β), and interleukin-6 (IL-6) in PSCs decreased significantly with duloxetine treatment (Fig. 4D). These findings suggested that duloxetine suppressed PSC activation and reduced the quantity of the proteins and mRNA expression that contribute to stromal stiffness and tumor-stromal interactions.

**Duloxetine suppressed the activation of Akt-ERK pathway via PP2A activation.** Protein phosphatase 2A (PP2A) is known as a tumor suppressor and is involved in the regulation of many cellular functions, including extracellular signal-regulated kinase (ERK) signaling (24). A previous study revealed that PP2A contributes to cellular quiescence (24,25). To confirm that duloxetine affects PP2A and suppresses PSC activation, the protein expression was confirmed. In the western blot analysis, the PP2A expression level was increased by duloxetine treatment (Fig. 4E). Also, duloxetine treatment decreased in Akt and ERK phosphorylation (Fig. 4E). These data suggested that duloxetine reversed PP2A activation, which led PSCs into a quiescent state.

**Discussion**

In this study, the pathway analysis using a public microarray data of CAFs showed aberration hubs in the ‘neuroactive ligand-receptor interaction’ pathway. This led to the identification of a promising compound, duloxetine. Duloxetine suppressed PSC activation and disrupted tumor-stromal interaction. Together, these experiments elucidated the potential role of duloxetine as an alternative drug for pancreatic cancer treatment.

From the microarray analysis, other pathways identified in the top 10 list were previously reported as targets of cell proliferation and adhesion. We focused on the neuroactive ligand-receptor interaction pathway because it is the only pathway whose relationship with PSC activation has not been reported. Lipid accumulation was detected in cells treated with all compounds related to this pathway;
Figure 4. Duloxetine suppresses tumor-stromal interactions by attenuating secretomes from PSCs. (A) Representative photomicrographs of invading and migrating SUIT-2 cells in monoculture and indirect coculture with drugs or supernatants following hematoxylin and eosin staining. Magnification, x100. Scale bar, 100 µm. (B) Graphs show the number of invading and migrating SUIT-2 cells. (C) Western blotting of extracellular matrix proteins in PSC supernatant and drug-treated PSC supernatant. (D) Relative mRNA expression of growth factors and cytokines associated with tumor-stromal interactions in PSCs treated with duloxetine. The expression levels of each gene were normalized to GAPDH. *P<0.05, **P<0.01, ****P<0.0001 vs. control group. PSCs, pancreatic stellate cells; PSN-SN, PSC supernatant; Dulo-SN, supernatant from PSCs treated with duloxetine; PP2A, protein phosphatase 2A; COL1A1, α1 type-1 collagen; POSTN, peristin; CTGF, connective tissue growth factor; HGF, hepatocyte growth factor; IL-1β, interleukin-1β; IL-6, interleukin-6; p, phosphorylated.
therefore, we selected duloxetine, which showed the highest lipid accumulation. Most of the drugs' targets related to this pathway are G protein-coupled receptors (GPCRs). GPCRs are located on the cell surface and are related to tumor cell proliferation and invasion in various types of tumors (26,27). More than 30% of approved drugs exert their therapeutic effects by acting on GPCRs (28). Therefore, they are recognized as potential targets of anti-cancer drugs (29). There are some reports that show the relationship between PSC activation and GPCRs. Cortes et al. observed that G protein-coupled estrogen receptor, a GPER, is a mechanosensor of PSCs and can remodel stromal tissue, thereby preventing tissue stiffness (30). Other research indicated that GPR68, a proton-sensing GPCR, was expressed in CAFs and acted as a mediator of the tumor microenvironment (31). These prior studies support targeting one of the GPCRs as a promising approach for suppressing PSC activation. However, this study did not clarify whether the suppression of activation is mediated by GPCRs and what structural differences exist in the GPCRs that exert therapeutic effects. Given that GPCRs are widely expressed across tissues and their role is mediated through various signaling pathways (32), further experiments are required to elucidate the mechanism of GPCR in PSC function.

The PSC supernatant enhanced the invasion and migration of PCCs as previously reported. These findings are due to enhanced tumor-stromal interactions (22). PCC invasion and migration were interrupted to a further extent by co-culturing with the supernatant from duloxetine-treated PSCs and not with duloxetine itself. This suggested that cytokines or proteins secreted by PSCs were suppressed by duloxetine. During activation, PSCs receive various stimuli from adjacent cells, and activated PSCs are potent to secrete inflammatory cytokines and ECM proteins (33). We calculated ECM proteins and cytokines secreted by activated PSCs and observed that these secretions were decreased by duloxetine. Together, we concluded that duloxetine not only has a toxic effect on PSCs, but can induce inactive PSC.

Treatment strategies for reshaping the tumor stroma have been widely discussed and investigated in the past decades. In clinical settings, expression of pro-tumorigenic markers and ECM components is correlated with a worse prognosis (34). In this study, PSCs treated with duloxetine produced less ECM components, including collagen and POSTN that constitute the tumor-supportive microenvironment (35). Therefore, converting pro-tumor PSCs into tumor-suppressing cells may be an ideal approach for treating pancreatic tumors. It has also been revealed that different fibroblast subtypes have different roles in tumorigenesis and treatment response (36). In our study, PSCs derived from different patient specimens showed different responses to duloxetine. However, we performed experiments with a limited number of PSCs and organoids from one PDAC patient sample. Further study is needed to investigate the response based on the clinical feature and changes in specific fibroblast subtype with duloxetine treatment.

The relationship between antidepressants and cancer has been discussed for over a decade. There is no strong evidence of a relationship between them; however, the relationship between antidepressants and carcinogenesis of colorectal cancer has been reported (37). Other cancers showed a tumor-suppressive effect by exhibiting antidepressant-like properties in a mouse experiment (38,39). Duloxetine has already been used in patients with chronic pains or painful chemotherapy-induced peripheral neuropathy (40,41); therefore, it is well-tolerated for clinical use. Kajiwara et al. recently demonstrated that duloxetine treatment improved cancer-associated pain in a PDAC mouse model (42). They stated that duloxetine inhibited the proliferation of PCCs and CAFs, which was consistent with our report. Based on our results, duloxetine is a potential drug for reducing the adverse effects of chemotherapy and enhancing the effect of chemotherapy by targeting stromal remodeling.

Acknowledgements

The authors would like to thank Ms. Emiko Manabe and Ms. Shoko Sadatomi (Department of Surgery and Oncology, Kyushu University Hospital, Fukuoka, Japan) for their technical assistance during experiments.

Funding

This study was supported in part by the Japan Society for the Promotion of Science Grants-in-Aid (B) and (C), and a Young Scientists Grant (grant nos. JP18H02880, JP19H03732, JP19K18153 and JP20H03754), the Takeda Science Foundation, Kobayashi Foundation for Cancer Research and The Shinnihon Foundation of Advanced Medical Treatment Research.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

AS, KN and MN conceived and designed the study. AS performed the experiments, data collection and wrote the manuscript. SM designed the experimental approach and contributed to data interpretation and discussion. WG, TS and CI helped with the investigation and formal analysis of data. NI and KO contributed to the methodology and data analysis. KN and MN supervised the project, obtained funding and confirm the authenticity of all the raw data. AS and KN revised the manuscript. MN approved the final version of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Written informed consent was obtained from all participants prior to using their pancreatic cancer surgical specimens for the establishment of pancreatic stellate cells and human organoids. This study was approved by the Ethics Committee of Kyushu University (approval no. IRB: 28-189; Fukuoka, Japan), and all experiments were conducted according to the Ethical Guidelines for Human Genome/Gene Research enacted by the Japanese Government and the Declaration of Helsinki.
Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Rawla P, Sunkara T and Gaduputi V: Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J Oncol 10: 10-27, 2019.

2. Gastroen J, Yuara S and Gil Z: Geminibatine resistance in pancreatic ductal adenocarcinoma. Drug Resist Updat 23: 55-68, 2015.

3. Parvathenani V, Kulkarni NS, Muth A and Gupta V: Drug repurposing: A promising tool to accelerate the drug discovery process. Drug Discov Today 24: 2076-2085, 2019.

4. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guiliams T, Latimer J, McNamee C, et al: Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov 18: 41-58, 2019.

5. Apte MV, Haber PS, Darby SJ, Rodgers SC, McLauchlan GW, Korenman MA, Pirolo RC and Alvarado T: Pancreatic stellate cells are activated by proinflammatory cytokines: Implications for pancreatic fibrogenesis. Gut 44: 534-541, 1999.

6. Apte MV, Wilson JS, Luega A and Pandol SJ: A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology 144: 1210-1219, 2013.

7. Bachem MG, Schüenemann M, Ramadan M, Siech M, Beger H, Buck A, Zhou S, Schmid-Kotsas A and Adler G: Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128: 907-921, 2005.

8. Bachem MG, Schneider E, Gross H, Weidenhach S, Schmid RM, Menke A, Siech M, Beger H, Grünert A and Adler G: Identification, characterization of pancreatic stellate cells in rats and humans. Gastroenterology 115: 421-432, 1998.

9. Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Thorne AE, Hwang CI, Baker LA, Chio II, et al: Identification, culture, and characterization of pancreatic stellate cells: A star on the rise in pancreatic diseases. J Clin Invest 120: 324-338, 2010.

10. Koikawa K, Ohuchida K, Ando Y, Kibe S, Nakayama H, Doig A, Guiliams T, Latimer J, McNamee C, et al: Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov 18: 41-58, 2019.

11. Endo S, Nakata K, Ohuchida K, Takesue S, Nakayama H, Takekawa T, Endo S, Abe T, Okumura T, Iwamoto C, et al: Basement membrane destruction by pancreatic stellate cell activation is involved in local invasion in pancreatic ductal adenocarcinoma. Cancer Lett 425: 65-77, 2018.

12. Sagara A, Nakata K, Yamashita T, Guan W, Zhong P, Matsumoto S, Endo S, Iwamoto C, Shindo K, Ikenna N, et al: New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer progression. Cancer Lett 425: 65-77, 2018.

13. Xiao Y, Zhang H, Ma Q, Huang R, Lu J, Liang X, Liu X, Zhang Z, Yu L, Pang J, et al: YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation. Cancer Lett 462: 51-60, 2019.

14. Jakubowska MA, Ferdek PE, Gerasimenko OV, Gerasimenko JV and Petersen OH: Nitric oxide signals are interlinked with calcium signals in normal pancreatic stellate cells upon oxidative stress and inflammation. Open Biol 6: 160149, 2016.
38. Tegowski M, Fan C and Baldwin AS: Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G1 arrest independent of DRD2. J Biol Chem 293: 15977-15990, 2018.

39. Gwynne WD, Hallett RM, Girgis-Gabardo A, Bojovic B, Dvorkin-Gheva A, Aarts C, Dias K, Bane A and Hassell JA: Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts. Oncotarget 8: 32101-32116, 2017.

40. Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, et al: Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial. JAMA 309: 1359-1367, 2013.

41. Hirayama Y, Ishitani K, Sato Y, Iyama S, Takada K, Murase K, Kuroda H, Nagamachi Y, Konuma Y, Fujimi A, et al: Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: A pilot randomized trial. Int J Clin Oncol 20: 866-871, 2015.

42. Kajiwara I, Sano M, Ichimaru Y, Oshima Y, Kitajima O, Hao H, Masamune A, Kim J, Ishii Y, Ijichi H, et al: Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effects. Pain 161: 2909-2919, 2020.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.